Podcasts about gliomas

The May 2024 replay features four episodes on neuro-oncology for brain cancer awareness month. The episode begins with Dr. Philipp Karschnia discussing the assessment of whether MTHFR polymorphisms affect the risk for leukoencephalopathy. The episode continues with Dr. Ingo Mellinghoff discussing new treatment opinions for isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas. The third interview leads into a conversation with Dr. Linda Liau on the study of vaccine-based therapy for GBM. The episode concludes with Dr. Teddy Totimeh talking about brain tumor programs in Asia and Africa. Podcast Links: MTHFR Polymorphisms and Leukoencephalopathy Risk in CNS Lymphoma Patients   New Treatment for IDH mt Gliomas  Study of Vaccine-Based Therapy for GBM Brain Tumor Programs in Asia and Africa  Article Links: https://doi.org/10.1212/WNL.0000000000207670  https://www.nejm.org/doi/full/10.1056/NEJMoa2304194 https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847 https://doi.org/10.1016/j.wneu.2023.04.067 Disclosures can be found at Neurology.org.

Glioblastoma is the most common malignant brain tumor and one of the most aggressive solid tumors. Much progress has been made in the understanding and classification of gliomas, but progress in terms of prolonging survival has been limited. Several recent investigational therapies are bringing new hope. Our guest today is Dr. Eric Wong from Brown University. He is an international expert on advanced treatments for glioblastoma and a Professor of Medicine, Radiation Oncology, Neurosurgery, and Neurology at Brown University. He was interviewed by Dr. Christoph Stretz, a Vascular and Critical Care neurologist at Brown. Series 5, Episode 6 Featuring: Guest: Dr. Eric Wong, Brown University Interviewer: Dr. Christoph Stretz, Brown University

Dr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas.

BUFFALO, NY- January 30, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 1, entitled, “XRCC1: a potential prognostic and immunological biomarker in LGG based on systematic pan-cancer analysis.” X-ray repair cross-complementation group 1 (XRCC1) is a pivotal contributor to base excision repair, and its dysregulation has been implicated in the oncogenicity of various human malignancies. However, a comprehensive pan-cancer analysis investigating the prognostic value, immunological functions, and epigenetic associations of XRCC1 remains lacking. In this new study, researchers Guobing Wang, Yunyue Li, Rui Pan, Xisheng Yin, Congchao Jia, Yuchen She, Luling Huang, Guanhu Yang, Hao Chi, and Gang Tian from Southwest Medical University, The Affiliated Hospital of Southwest Medical University, Yibin Hospital of T.C.M, Medical School of Nanchang University, Fourth Military Medical University, and Ohio University aimed to address this knowledge gap by conducting a systematic investigation employing bioinformatics techniques across 33 cancer types. “Our analysis encompassed XRCC1 expression levels, prognostic and diagnostic implications, epigenetic profiles, immune and molecular subtypes, Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), immune checkpoints, and immune infiltration, leveraging data from TCGA, GTEx, CELL, Human Protein Atlas, Ualcan, and cBioPortal databases.” Notably, XRCC1 displayed both positive and negative correlations with prognosis across different tumors. Epigenetic analysis revealed associations between XRCC1 expression and DNA methylation patterns in 10 cancer types, as well as enhanced phosphorylation. Furthermore, XRCC1 expression demonstrated associations with TMB and MSI in the majority of tumors. Interestingly, XRCC1 gene expression exhibited a negative correlation with immune cell infiltration levels, except for a positive correlation with M1 and M2 macrophages and monocytes in most cancers. Additionally, the researchers observed significant correlations between XRCC1 and immune checkpoint gene expression levels. Lastly, their findings implicated XRCC1 in DNA replication and repair processes, shedding light on the precise mechanisms underlying its oncogenic effects. “Overall, our study highlights the potential of XRCC1 as a prognostic and immunological pan-cancer biomarker, thereby offering a novel target for tumor immunotherapy." DOI - https://doi.org/10.18632/aging.205426 Corresponding authors - Guanhu Yang - guanhuyang@gmail.com, Hao Chi - Chihao7511@163.com, and Gang Tian - tiangang@swmu.edu.cn Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, X-ray repair cross-complementation group 1, pan-cancer, prognosis, immune infiltration, tumor microenvironment About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Dr. Iyad Alnahhas interviews Dr. Amanda Saratsis about her recent manuscript entitled: "H3K27M Mutant Glioma: Disease Definition and Biological Underpinnings", published online in Neuro-Oncology in October 2023. Read Paper

Dr. Francis Deng summarizes major highlights of current research and future trends from the September 2023 Neuroradiology Centennial content. Functional MRI in Neuro-Oncology: State of the Art and Future Directions. Pasquini et al. Radiology 2023; 308(3):e222028. Neuroimaging in Dementia: More than Typical Alzheimer Disease. Haller et al. Radiology 2023; 308(3):e230173. MRI of the Brain: What Is Driving Innovation in 2023? Hess. Radiology 2023; 308(3):e231657.  Challenges of Preparing for Diagnostic Radiology Call. Isikbay et al. Radiology 2023; 308(3):e230421. Neurochemical Differences between 1p/19q Codeleted and Noncodeleted IDH-mutant Gliomas by in Vivo MR Spectroscopy. Branzoli et al. Radiology 2023; 308(3):e223255. Correlating Quantitative MRI-based Apparent Diffusion Coefficient Metrics with 24-month Neurodevelopmental Outcomes in Neonates from the HEAL Trial. Calabrese et al. Radiology 2023; 308(3):e223262.

Today, you'll learn about a tiny device that could have a huge impact on brain cancer, some news about keto and fertility, and the truth about the old saying opposites attract. Microbot Tumor Killer “Microdevices implanted into tumors offer new way to treat brain cancer.” EurekAlert! 2023. “Gliomas.” by Fassil B. Mesfin & Mohammed A. Al-Dhahir. 2023. “Treatment of Adult Gliomas: A Current Update.” by Joo Ho Lee & Chan Woo Wee. 2022. Keto & PCOS “Women with PCOS on keto diet may see improvements in fertility.” EurekAlert! 2023. “Advantages and Disadvantages of the Ketogenic Diet: A Review Article.” by Jennifer T. Batch, et al. 2020. “Polycystic ovary syndrome (PCOS).” Mayo Clinic. 2022. Do Opposites Attract? “Study confirms it: Opposites don't actually attract.” EurekAlert! 2023. “Paula Abdul - Opposites Attract (Official Music Video).” YouTube. 2009. “New academic study links rising income inequality to ‘assortative mating'.” by Rich Morin. 2014. “Evidence of correlations between human partners based on systematic reviews and meta-analyses of 22 traits and UK Biobank Analysis of 133 traits.” by Tanya B. Horwitz, et al. 2023. Follow Curiosity Daily on your favorite podcast app to get smarter with Calli and Nate — for free! Still curious? Get exclusive science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers. Hosted on Acast. See acast.com/privacy for more information.

Dr. Iyad Alnahhas interviews Drs. Kelly Hotchkiss and Mustafa Khasraw about their recently published review entitled: "Dendritic cell vaccine trials in gliomas: untangling the lines", published online in Neuro-Oncology in June 2023. Read Paper

GRACIAS DR.JESUS MARTIN FERNANDEZ..por tu compromiso, integridad y pasión por divulgar los secretos del CEEBRO y de los GLIOMAS.. Y LA NEUROCIRUGIA CON PACIENTE DESPIERTO, desde hemisferio derecho y con la colaboracion de IA.. PARA CONSERVAR Y HACER SIRUGIA A LA CARTA.. calidad de vida.. GRACIAS.. DR.LUIS JIMENEZ.. por ser catedratico, neuroinvestigador, de Venezuela.. y sobre todo comprometido por APLICACION NEUROCIENCIAS.. PARA EL BIENESTAR HUMANO . GRACIAS.. MARISAPATIÑO. EmbajadoradePaz. Mentora Neurociencias APLICADAS.

Dr. Ingo K. Mellinghoff discusses his paper, "Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma". Show references: https://pubmed.ncbi.nlm.nih.gov/37272516/

Dr. Kathryn Nevel talks with Dr. Ingo Mellinghoff about how vorasidenib improved progression-free survival in patients with Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas. Read the related article in The New England Journal of Medicine. Visit NPUb.org/Podcast for associated article links.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a novel therapeutic approach that induced antigen tolerance in an MS mouse model, the association between epileptiform activity and ICU outcomes, and an agent, vorasidenib, that slows low-grade gliomas.

Description: Dr. Maya Graham interviews Drs. Jasmin Jo, Craig Horbinski and David Schiff about their recent manuscript entitled: "Epidemiology, biology and management of venous thromboembolism in gliomas: an interdisciplinary review", published online in Neuro-Oncology in April 2023. Read Paper

Dr. Ankush Bhatia interviews Dr.François Ducray about his and his team's recent manuscript entitled:"Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network study", published online in Neuro-Oncology in March 2023.  

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.04.05.535697v1?rss=1 Authors: Zheng, J., Wang, L., Zhao, S., Zhang, W., Chang, Y., Dheer, A., Gao, S., Xu, S., Ayasoufi, K., Al-kharboosh, R., Xie, M., Johnson, A. J., Dong, H., Wu, L.-J. Abstract: Triggering receptor expressed on myeloid cells 2 (TREM2) was recently highlighted as a novel immune suppressive marker in peripheral tumors. The aim of this study was to characterize TREM2 expression in gliomas and investigate its contribution in glioma progression by using Trem2-/- mouse line. Our results showed that higher TREM2 expression was correlated with poor prognosis in glioma patients. Unexpectedly, TREM2 deficiency did not have a beneficial effect in a pre-clinical model of glioma. The increased TREM2 expression in glioma was likely due to increased myeloid cell infiltration, as evidenced by our single-cell analysis showing that almost all microglia and macrophages in gliomas were TREM2+. Furthermore, we found that deficiency of TREM2 impaired tumor-myeloid phagocytosis and MHCII presentation, and significantly reduced CD4+ T cells in tumor hemispheres. Our results revealed a previously unrecognized protective role of tumor-myeloid TREM2 in promoting MHCII-associated CD4+ T cell response against gliomas. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Epileptologist Jessica W. Templer, MD; Neuro-oncologist, Karan S. Dixit, MD; and Neurosurgeon Matthew Tate, MD, PhD, join this episode of the Better Edge podcast to discuss management strategies for patients with low grade glioma. They are members of the Northwestern Medicine Low Grade Glioma Program, which is part of Northwestern Medicine Malnati Brain Tumor Institute.

Concluding their Journey to the Centre of the Brain, Michael and Josh tackle one of the most challenging and difficult cancers in modern oncology: high-grade gliomas. All of the usual suspects are here: irrevocable, progressive disease, limited treatment options and a gulf in evidence so large it makes the Grand Canyon look like a muddy footprint. All in all, not the most optimistic of OftiM episodes, but Josh and Michael will tackle it anyway so you don't have to. And remember: always refer your fit GBM patients to a friendly neighbourhood trials unit near you!Links to studies discussed in this episode (subscription may be required):EORTC 26981-22981 NCIC CE3 (aka the “Stupp study"): https://www.nejm.org/doi/full/10.1056/nejmoa043330RTOG 0825: https://www.nejm.org/doi/full/10.1056/nejmoa1308573Brada et al: https://ascopubs.org/doi/full/10.1200/JCO.2009.27.1932?role=tabTaal et al: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70314-6/fulltextWick et al: https://www.nejm.org/doi/full/10.1056/nejmoa1707358For more episodes, resources and blog posts, visit inquisitiveonc.comFind us on Twitter @InquisitiveOncIf you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comVisit us at your new website www.inquisitiveonc.com for our latest episodes, links to resources and musings!Art courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Note: This podcast is for educational purposes only. If you are unwell seek medical advice Hosted on Acast. See acast.com/privacy for more information.

Description: Dr. Ankush Bhatia interviews Drs. Julie Miller, Nicolas Gonzalez Castro, Samuel McBrayer and Patrick Wen about their recent manuscript, entitled: "Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions", published online in Neuro-Oncology in October 2022. Full Report

Ashley Ghiaseddin, M.D., highlights treatment strategies for malignant gliomas. He shares challenges to therapeutic options, the standard approaches to treatment, novel treatment strategies and when it is important to refer to the specialists at UF Health Shands Hospital.

In episdoe 8, I discuss the basic treatment schedule for adult patients with gliomas. I describe the preoperative workup, surgery and then the adjuvant treatment that is usually given – radiotherapy and chemotherapy. More detailed episodes will cover radiotherapy and chemotherapy but here I cover that overall management plan that usually applies for adult glioma.

In this episode of the Brain Tumour Podcast Dr Daved Walker gives an introduction to subject of Low Grade Gliomas, particularly as they pertain to adults. I describe the main subtypes, that is astrocytoma and oligodendroglioma, and how these tumours are differentiated. I talk about the investigations, and then the controversy around the approach to management.

In this episode of The Brain Tumour Podcast is an Introduction to Gliomas. Gliomas are common tumours of the brain. But there are many different varieties so this episode gives an introduction to Gliomas, and describes the common glioma types, who they affect and why precise pathological and molecular classification is used when diagnosing these tumours.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.11.08.515720v1?rss=1 Authors: Barron, T., Yalcin, B., Mochizuki, A., Cantor, E., Shamardani, K., Tlais, D., Franson, A., Lyons, S., Mehta, V., Maleki Jahan, S., Taylor, K. R., Keough, M. B., Xu, H., Su, M., Quezada, M. A., Woo, P. J., Fisher, P. G., Campen, C. J., Partap, S., Koschmann, C., Monje, M. Abstract: Pediatric high-grade gliomas are the leading cause of brain cancer-related death in children. High-grade gliomas include clinically and molecularly distinct subtypes that stratify by anatomical location into diffuse midline gliomas (DMG) such as diffuse intrinsic pontine glioma (DIPG) and hemispheric high-grade gliomas. Neuronal activity drives high-grade glioma progression both through paracrine signaling(1,2) and direct neuron-to-glioma synapses(3-5). Glutamatergic, AMPA receptor-dependent synapses between neurons and malignant glioma cells have been demonstrated in both pediatric(3) and adult high-grade gliomas(4), but neuron-to-glioma synapses mediated by other neurotransmitters remain largely unexplored. Using whole-cell patch clamp electrophysiology, in vivo optogenetics and patient-derived glioma xenograft models, we have now identified functional, tumor-promoting GABAergic neuron-to-glioma synapses mediated by GABAA receptors in DMGs. GABAergic input has a depolarizing effect on DMG cells due to NKCC1 expression and consequently elevated intracellular chloride concentration in DMG tumor cells. As membrane depolarization increases glioma proliferation(3), we find that the activity of GABAergic interneurons promotes DMG proliferation in vivo. Increasing GABA signaling with the benzodiazepine lorazepam, a positive allosteric modulator of GABAA receptors commonly administered to children with DMG for nausea or anxiety, increases GABAA receptor conductance and increases glioma proliferation in orthotopic xenograft models of DMG. Conversely, levetiracetam, an anti-epileptic drug that attenuates GABAergic neuron-to-glioma synaptic currents, reduces glioma proliferation in patient-derived DMG xenografts and extends survival of mice bearing DMG xenografts. Concordant with gene expression patterns of GABAA receptor subunit genes across subtypes of glioma, depolarizing GABAergic currents were not found in hemispheric high-grade gliomas. Accordingly, neither lorazepam nor levetiracetam influenced the growth rate of hemispheric high-grade glioma patient-derived xenograft models. Retrospective real-world clinical data are consistent with these conclusions and should be replicated in future prospective clinical studies. Taken together, these findings uncover GABAergic synaptic communication between GABAergic interneurons and diffuse midline glioma cells, underscoring a tumor subtype-specific mechanism of brain cancer neurophysiology with important potential implications for commonly used drugs in this disease context. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Resumo da semana: - A combinação de duas terapias direcionadas melhora a taxa de resposta em gliomas pediátricos de baixo grau (Journal of Clinical Oncology) - Extensão da ressecção do tumor influencia a sobrevivência em pacientes pediátricos com gliomas de alto grau (JAMA Network Open) - Estimulação cerebral leva a melhorias duradouras na memória (Nature Neuroscience) - Gene associado ao risco de Alzheimer pode fornecer estratégia de tratamento para prevenir a perda de visão por glaucoma (Immunity) - Estudo sugere associação causal entre doença renal crônica e maior risco de hemorragia intracerebral espontânea (JAMA Neurology) - Processo de edição do RNA pode ser a base do risco genético de doenças autoimunes (Nature) - Terapia digital pode fornecer alívio dos sintomas de zumbido no ouvido (Frontiers in Neurology) - Maior nível de folato de glóbulos vermelhos pré-concepção reduz o risco de cardiopatia congênita na prole (Annals of Internal Medicine) Veja mais notícias em news.med.br Este podcast é oferecido por HiDoctor – o software médico mais usado em consultórios e clínicas no país.

Dr. Iyad Alnahhas interviews Drs. Jennifer Cotter and Kee Kiat Yeo about their recent paper entitled: ""Multi-institutional study of the frequency, genomic landscape and outcome of IDH-mutant glioma in pediatrics", published online in Neuro-Oncology in May 2022. Full Article

Gliomas have long been considered one of the most daunting forms of cancer, but advances in research, imaging, and treatments are turning the tide on these brain tumors. Dr. Elizabeth Maher, Director of UT Southwestern's translational research program in neuro-oncology, and Dr. Toral Patel, a neurosurgeon who specializes in advanced surgical techniques, provide a glimpse into the precise and personalized treatment options now available to patients.

WATCH THE VIDEO WEBCAST HERE: https://youtu.be/5TYFsjh91Tw Listen in as our host, Dr. Brenda Weigel from the University of Minnesota, is joined by Dr. Robbie Majzner - an Assistant Professor of Pediatrics in the Division of Hematology and Oncology at Stanford University's School of Medicine. Dr. Majzner goes into great detail about his recent clinical trial on GD2-CAR T cell therapy for H3K27M-mutated Diffuse Midline Gliomas - the findings, the process, and what the future holds. You can read more about Dr. Majzner's study here: https://www.nature.com/articles/s41586-022-04489-4 Have any thoughts? Questions? Ideas for future topics? Email us at TWIPO@solvingkidscancer.org. Subscribe to TWIPO to get notifications of new uploads. Want to listen to TWIPO's past episodes? Visit www.solvingkidscancer.org/podcast

Dr. Evan Noch interviews Dr. Joanna Phillips about her and her team manuscript entitled: "PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications", published online in Neuro-Oncology in March 2022.

Co-hosts Stephanie Winn and Chris Joyce sit down with Dr. Orwa Aboud, a Neuro-Oncologist treating patients with a variety of primary brain tumors such as glioblastoma and low-grade gliomas to discuss advances in treatments as well as signs and symptoms patients should be aware of when it comes to cancers of the brain. To learn more about the UC Davis Comprehensive Cancer Center, visit https://health.ucdavis.edu/cancer.

Durante el último año, el Grupo Cochrane de Cáncer ginecológico, neurooncología y otros cánceres ha publicado una serie de nuevas revisiones sistemáticas sobre temas prioritarios para la comunidad relacionada con los tumores cerebrales. Estas fueron seleccionadas a partir de las preguntas sin respuesta más importantes identificadas por los pacientes, el público y los médicos. En este podcast se habla sobre una de las revisiones, publicada en marzo de 2022, en la que se analiza la evidencia de algunas de las pruebas que podrían ayudar a planificar el tratamiento de los pacientes con glioma. Este podcast ha sido traducido por Yasmín García y locutado por Josefina Bendersky del Centro Cochrane Iberoamericano.

Durante el último año, el Grupo Cochrane de Cáncer ginecológico, neurooncología y otros cánceres ha publicado una serie de nuevas revisiones sistemáticas sobre temas prioritarios para la comunidad relacionada con los tumores cerebrales. Estas fueron seleccionadas a partir de las preguntas sin respuesta más importantes identificadas por los pacientes, el público y los médicos. En este podcast se habla sobre una de las revisiones, publicada en marzo de 2022, en la que se analiza la evidencia de algunas de las pruebas que podrían ayudar a planificar el tratamiento de los pacientes con glioma. Este podcast ha sido traducido por Yasmín García y locutado por Josefina Bendersky del Centro Cochrane Iberoamericano.

Over the last year, Cochrane Neuro-Oncology have been publishing a series of new systematic reviews on priority topics for the brain tumour community. These were selected from the most important unanswered questions identified by patients, the public and practitioners. In this podcast, Kathreena Kurian from the University of Bristol in the UK tells us about one of the reviews, which was published in March 2022, looking at the evidence on some of the tests that might help in planning the treatment of patients with a glioma.

Over the last year, Cochrane Neuro-Oncology have been publishing a series of new systematic reviews on priority topics for the brain tumour community. These were selected from the most important unanswered questions identified by patients, the public and practitioners. In this podcast, Kathreena Kurian from the University of Bristol in the UK tells us about one of the reviews, which was published in March 2022, looking at the evidence on some of the tests that might help in planning the treatment of patients with a glioma.

Dr. Ankush Bhatia interviews Dr. Jack Grinband about his recent manuscript entitled "BOLD Asynchrony Elucidates Tumor Burden in IDH-Mutated Gliomas", published online in Neuro-Oncology in July 2021

Dr. Maya Graham interviews Dr. Nduka Amankulor about the recent manuscript entitled: "Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles" published online in Neuro-Oncology in July 2021.

Hour 4 - Addison Gould (4) fights optic pathway gliomas, Jeff Kitaeff (71) discusses his fight with lung cancer, Arbella Insurance CEO John Donohue, With Cam Newton missing practice will Mac Jones be the starter See omnystudio.com/listener for privacy information.

Addison Gould (4) has optic pathway gliomas she's with her parents Jillian and Graham Addison was diagnosed with optic pathway gliomas in 2019 but an August 2020 MRI revealed substantially growth over the year and the left optic glioma was making her left eye protrude from its socket rendering her essentially blind in that eye.  See omnystudio.com/listener for privacy information.

Dr. Maya Graham interviews Dr. Nancy Ann Oberheim Bush about her and her team's paper entitled " Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas" published online in Neuro-Oncology in April 2021

En este último episodio de la primera temporada, discutiremos acerca de los gliomas o tumores cerebrales. Discutiremos acerca de su clacificación, importancia y hablaremos de una modalidad muy importante en su tratamiento. --- Send in a voice message: https://anchor.fm/neurall-research/message

Perfusion technique allows Radiologists to decipher tumor vs. post-treatment effect. PWI is a very effective tool in terms of treating Gliomas, specifically Glioblastomas as they are the most common. We really appreciate Dr. Hu for sitting with us and helping to provide insight for those looking to advance their knowledge of imaging/treatment.

Welcome to the Sterile Technique Podcast! It's the podcast about Surgical Technology. Whether you are a CST or CSFA, this podcast helps you earn CE credits and improve your surgery skills in the OR. This episode discusses the cover article of the March 2021 issue of The Surgical Technologist, which is the official journal of the Association of Surgical Technologists (AST). The article is titled, "5-ALA Fluorescence-Guided Resection of Malignant Gliomas". "Scrub in" at steriletpodcast.com and on Twitter, @SterileTPodcast (twitter.com/SterileTPodcast). This podcast is a Dybas Media production. Sound effects adapted from GarageBand and sindhu.tms at https://freesound.org/people/sindhu.tms/sounds/169065/ and licensed courtesy of https://creativecommons.org/licenses/by-nc/3.0/.

Dr. Iyad Alnahhas interviews Dr. Houton Noushmehr about his recent paper "A serum-based DNA methylation assay provides accurate detection of glioma", published online in Feb 2021 in Neuro-Oncology

Scott Megaffin, CEO of Adastra Pharmaceuticals, Inc., a company focused on the treatment of cancers with high unmet needs (such as high-grade gliomas), discusses positive top-line data from their Phase 1b clinical trial conducted by the National Cancer Institute evaluating zotiraciclib (ZTR/TG02) in combination with temozolomide (TMZ) in patients with recurrent high-grade gliomas, which have a near-100% mortality rate and very limited therapeutic options. He also talks about Adastra's plans for the future development of ZTR. Scott Megaffin, Chief Executive Officer at Adastra Pharmaceuticals Inc. Mr. Megaffin has more than 30 years of related experience in the pharmaceutical industry. Scott plans and directs all aspects of Adastra operational objectives, policies and initiatives. He is responsible for the development of the functional business strategy of Adastra, including investor relations and communication of the corporate vision and supporting values. Prior to joining Adastra, Mr. Megaffin served as President of Churchill Pharmaceuticals LLC, sold to Sun Pharma in 2018. Scott has held numerous global strategic and operational positions of increasing responsibility including Senior Vice President of Commercial Development for Onconova Therapeutics, Inc., also Cephalon, Adolor, Yamounchi and Bristol-Myers Squibb. He has led six global drug approvals and development programs, within a variety of therapeutic categories including oncology, hematology, virology, critical care, anti-infectives, pain and inflammation. Scott received a B.S. in Biology from Pittsburg State University.

Dr. Evan Noch interviews Dr. Jill Barnholtz-Sloan about her recent paper "Epidemiology of Brainstem High-Grade Gliomas in Children and Adolescents in the United States, 2000-2017" published online in Neuro-Oncology in December 2020.

NEURORADIOLOGY GLIOMAS

In part 3 of a 3-part series, Howard Colman, MD, PhD, FAAN, discusses his article, "Adult Gliomas" from the December Neuro-oncology Continuum issue. This article and the accompanying Continuum Audio interview are open to all until March 1, 2021 at continpub.com/AdultGli.

In part 2 of a 3-part series, Howard Colman, MD, PhD, FAAN, discusses his article, "Adult Gliomas" from the December Neuro-oncology Continuum issue. This article and the accompanying Continuum Audio interview are open to all until March 1, 2021 at continpub.com/AdultGli.

In part 1 of a 3-part series, Howard Colman, MD, PhD, FAAN, discusses his article, "Adult Gliomas" from the December Neuro-oncology Continuum issue. This article and the accompanying Continuum Audio interview are open to all until March 1, 2021 at continpub.com/AdultGli.

Dr. Iyad Alnahhas talks with Dr. Felix Sahm about his recently published article in Neuro-Oncology entitled: "A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR," published online on November 1, 2020.

Dr. Alireza Mansouri talks with Dr. Lorenzo Bello about his recently published article in Neuro-Oncology entitled: "Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas," published online on October 13, 2020.

Go online to PeerView.com/BQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF-1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. In this educational on-demand activity, an expert panel provides insights into the expanding landscape of targeted therapies and discusses optimal clinical decision-making for patients with NF-1 and NF-1─related plexiform neurofibromas based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF-1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas and other NF-1–associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF-1–related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF-1–related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF-1–related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.

Go online to PeerView.com/BQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF-1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. In this educational on-demand activity, an expert panel provides insights into the expanding landscape of targeted therapies and discusses optimal clinical decision-making for patients with NF-1 and NF-1─related plexiform neurofibromas based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF-1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas and other NF-1–associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF-1–related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF-1–related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF-1–related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.

Go online to PeerView.com/BQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF-1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. In this educational on-demand activity, an expert panel provides insights into the expanding landscape of targeted therapies and discusses optimal clinical decision-making for patients with NF-1 and NF-1─related plexiform neurofibromas based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF-1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas and other NF-1–associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF-1–related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF-1–related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF-1–related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.

Go online to PeerView.com/BQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF-1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. In this educational on-demand activity, an expert panel provides insights into the expanding landscape of targeted therapies and discusses optimal clinical decision-making for patients with NF-1 and NF-1─related plexiform neurofibromas based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF-1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas and other NF-1–associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF-1–related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF-1–related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF-1–related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.

Go online to PeerView.com/BQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF-1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. In this educational on-demand activity, an expert panel provides insights into the expanding landscape of targeted therapies and discusses optimal clinical decision-making for patients with NF-1 and NF-1─related plexiform neurofibromas based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF-1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas and other NF-1–associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF-1–related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF-1–related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF-1–related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.

Go online to PeerView.com/BQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF-1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. In this educational on-demand activity, an expert panel provides insights into the expanding landscape of targeted therapies and discusses optimal clinical decision-making for patients with NF-1 and NF-1─related plexiform neurofibromas based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF-1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas and other NF-1–associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF-1–related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF-1–related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF-1–related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.

Go online to PeerView.com/BQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF-1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. In this educational on-demand activity, an expert panel provides insights into the expanding landscape of targeted therapies and discusses optimal clinical decision-making for patients with NF-1 and NF-1─related plexiform neurofibromas based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF-1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas and other NF-1–associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF-1–related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF-1–related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF-1–related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.

Go online to PeerView.com/BQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF-1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. In this educational on-demand activity, an expert panel provides insights into the expanding landscape of targeted therapies and discusses optimal clinical decision-making for patients with NF-1 and NF-1─related plexiform neurofibromas based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF-1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas and other NF-1–associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF-1–related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF-1–related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF-1–related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.11.02.364711v1?rss=1 Authors: Zhao, Z., Chen, J., Bao, Z., Chai, R., Zhang, K.-n., Wu, L., Liu, H., Mu, Q., Hu, H., Zeng, F., Wang, Z., Li, G., Chang, Y., Wang, Q., Wu, F., Zhang, Y., Liu, Y., Zhang, W., Kang, C., Wang, J., Tao, R., Wang, Q., Jiang, T. Abstract: Activating alterations of the MET gene are well-characterized oncogenic drivers, and MET inhibitors could successfully treat several tumor types with MET alterations, including gliomas with PTPRZ1-MET fusion. However, the full diversity and prevalence of MET alterations in gliomas are still lacking to accurately identify a subset of patients likely to benefit from MET inhibitor treatment. Here, we interrogated genomic profiles of 1,351 gliomas, and further identify 60 cases harboring MET alterations, including MET fusions and various MET exon skipping events. MET RNA alterations, but not MET amplification, are highly enriched in the secondary glioblastomas (sGBM) with significantly worse prognosis. Further molecular analysis has shown that MET RNA alterations acting an additive effects of MET overexpression are induced in the course of glioma evolution. In vitro and clinical studies indicate cells and patients harboring MET alterations have better response to MET inhibitors. Collectively, these data suggest that a subgroup of gliomas harboring MET alterations likely to have benefit from MET-targeted therapy. Copy rights belong to original authors. Visit the link for more info

A lot can happen in two years. You might have matched into residency, graduated from fellowship, had a kid... Or several phase II trials in low grade glioma research could have been published. Since the original airing of this episode in May 2018, there have been a few updates in neuro-oncology. We'll cover some of the major ones this week in the BrainWaves podcast. Produced by James E. Siegler, Brian Nahed and Jorg Dietrich. Music courtesy of Ian Sutherland, Lovira, and Lee Roosevere. The opening theme was composed by Jimothy Dalton. Sound effects by Mike Koenig and Daniel Simion. Unless otherwise mentioned in the podcast, no competing financial interests exist in the content of this episode. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast. REFERENCES McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, Olivi A, Brem H and Quinones-Hinojosa A. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63:700-7; author reply 707-8. Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR and Mehta MP. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30:3065-70. Schiff D. Low-grade Gliomas. Continuum (Minneap Minn). 2017;23:1564-1579. Wen PY and Huse JT. 2016 World Health Organization Classification of Central Nervous System Tumors. Continuum (Minneap Minn). 2017;23:1531-1547. Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary JP, Kwok Y, Yu HM, Laack NN, Schultz CJ, Gray HJ, Robins HI, Mehta MP and Chakravarti A. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. JAMA Oncol. 2018;4:1405-1409. van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T and Idbaih A. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncol. 2018;19:1170-1179. Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ and Fouladi M. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 2019;20:1011-1022. Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL, Timmers CD, Becker AP, Salavaggione AL, Liu Z, Aldape K, Brachman DG, Gertler SZ, Murtha AD, Schultz CJ, Johnson D, Laack NN, Hunter GK, Crocker IR, Won M and Chakravarti A. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020:JCO1902983. Breen WG, Anderson SK, Carrero XW, Brown PD, Ballman KV, O'Neill BP, Curran WJ, Abrams RA, Laack NN, Levitt R, Galanis E, Buckner JC and Shaw EG. Final report from Intergroup NCCTG 86-72-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma. Neuro Oncol. 2020;22:830-837. Ullrich NJ, Prabhu SP, Reddy AT, Fisher MJ, Packer R, Goldman S, Robison NJ, Gutmann DH, Viskochil DH, Allen JC, Korf B, Cantor A, Cutter G, Thomas C, Perentesis JP, Mizuno T, Vinks AA, Manley PE, Chi SN, Kieran MW and Consortium NFCT. A Phase II Study of Continuous Oral mTOR Inhibitor Everolimus for Recurrent, Radiographic-Progressive Neurofibromatosis Type 1-Associated Pediatric Low-Grade Glioma: A Neurofibromatosis Clinical Trials Consortium Study. Neuro Oncol. 2020.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.10.244343v1?rss=1 Authors: Sienkiewicz, K., Chen, J., Chatrath, A., Lawson, J. T., Sheffield, N. C., Zhang, L., Ratan, A. Abstract: Joint analysis of multiple genomic data types can facilitate the discovery of complex mechanisms of biological processes and genetic diseases. We present a novel data integration framework based on non-negative matrix factorization that uses patient similarity networks. Our implementation supports continuous multi-omic datasets for molecular subtyping and handles missing data without using imputation, making it more efficient for genome-wide assays in large cohorts. Applying our approach to gene expression, microRNA expression, and methylation data from patients with lower grade gliomas, we identify a subtype with a significantly poorer prognosis. Tumors assigned to this subtype are hypomethylated genome-wide with a gain of AP-1 occupancy in the demethylated distal enhancers. These tumors' genomic profiles are similar to Grade IV gliomas: they are enriched for somatic chr7 gain, chr10 loss, and other molecular events that have yet to be used in the diagnosis of lower-grade gliomas as per the current WHO guidelines. Copy rights belong to original authors. Visit the link for more info

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.07.15.204933v1?rss=1 Authors: Bangalore Yogananda, C. G., Shah, B. R., Yu, F. F., Pinho, M. C., Nalawade, S. S., Murugesan, G. K., Wagner, B. C., Mickey, B., Patel, T., Fei, B., Madhuranthakam, A. J., Maldjian, J. A. Abstract: Background: One of the most important recent discoveries in brain glioma biology has been the identification of the isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion status as markers for therapy and prognosis. 1p/19q co-deletion is the defining genomic marker for oligodendrogliomas and confers a better prognosis and treatment response than gliomas without it. Our group has previously developed a highly accurate deep-learning network for determining IDH mutation status using T2-weighted MRI only. The purpose of this study was to develop a similar 1p/19q deep-learning classification network. Methods: Multi-parametric brain MRI and corresponding genomic information were obtained for 368 subjects from The Cancer Imaging Archive (TCIA) and The Cancer Genome Atlas (TCGA). 1p/19 co-deletions were present in 130 subjects. 238 subjects were non co-deleted. A T2w image only network (1p/19q-net) was developed to perform 1p/19q co-deletion status classification and simultaneous single-label tumor segmentation using 3D-Dense-UNets. Three-fold cross-validation was performed to generalize the network performance. ROC analysis was also performed. Dice-scores were computed to determine tumor segmentation accuracy. Results: 1p/19q-net demonstrated a mean cross validation accuracy of 93.46% across the 3 folds (93.4%, 94.35%, and 92.62%, standard dev=0.8) in predicting 1p/19q co-deletion status with a sensitivity and specificity of 0.90 +/- 0.003 and 0.95 +/- 0.01, respectively and a mean AUC of 0.95 +/- 0.01. The whole tumor segmentation mean Dice-score was 0.80 +/- 0.007. Conclusion: We demonstrate high 1p/19q co-deletion classification accuracy using only T2-weighted MR images. This represents an important milestone toward using MRI to predict glioma histology, prognosis, and response to treatment. Copy rights belong to original authors. Visit the link for more info

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.05.30.124230v1?rss=1 Authors: Bangalore Yogananda, C. G., Shah, B. R., Nalawade, S., Murugesan, G. K., Yu, F. F., Pinho, M. C., Wagner, B. C., Mickey, B., Patel, T. R., Fei, B., Madhuranthakam, A. J., Maldjian, J. A. Abstract: PURPOSE: Methylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) promoter results in epigenetic silencing of the MGMT enzyme and confers an improved prognosis and treatment response in gliomas. The purpose of this study was to develop a deep-learning network for determining the methylation status of the MGMT Promoter in gliomas using T2-w magnetic resonance images only. METHODS: Brain MRI and corresponding genomic information were obtained for 247 subjects from The Cancer Imaging Archive (TCIA) and The Cancer Genome Atlas (TCGA). 163 subjects had a methylated MGMT promoter. A T2-w image only network (MGMT-net) was developed to determine MGMT promoter methylation status and simultaneous single label tumor segmentation. The network was trained using 3D-Dense-UNets. Three-fold cross-validation was performed to generalize the network's performance. Dice-scores were computed to determine tumor segmentation accuracy. RESULTS: MGMT-net demonstrated a mean cross validation accuracy of 94.73% across the 3 folds (95.12%, 93.98%, and 95.12%, standard dev=0.66) in predicting MGMT methylation status with a sensitivity and specificity of 96.31% +/-0.04 and 91.66% +/-2.06, respectively and a mean AUC of 0.93 +/-0.01. The whole tumor segmentation mean Dice-score was 0.82 +/- 0.008. CONCLUSION: We demonstrate high classification accuracy in predicting the methylation status of the MGMT promoter using only T2-w MR images that surpasses the sensitivity, specificity, and accuracy of invasive histological methods such as pyrosequencing, methylation-specific PCR, and immunofluorescence methods. This represents an important milestone toward using MRI to predict glioma histology, prognosis, and response to treatment. Copy rights belong to original authors. Visit the link for more info

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.04.24.060830v1?rss=1 Authors: Di Ieva, A., Russo, C., Le Reste, P.-J., Magnussen, J. M., Heller, G. Abstract: Susceptibility-weighted imaging (SWI) is a technique useful for evaluation of the internal structures of brain tumors, including microvasculature and microbleeds. Intratumoral patterns of magnetic susceptibility can be quantified by means of fractal analysis. Here, we propose a radiomics methodological pipeline to merge advanced fractal-based computational modelling with statistical analysis to objectively characterize the fingerprint of gliomas and brain metastases. Forty-seven patients with glioma (grades II-IV, according to the WHO 2016 classification system) and fourteen with brain metastases underwent 3 Tesla MRI using a SWI protocol. All images underwent computational analysis aimed to quantify three Euclidean parameters (related to tumor and SWI volume) and five fractal-based parameters (related to the pixel distribution and geometrical complexity of the SWI patterns). Principal components analysis, linear and quadratic discriminant analysis, K-nearest neighbor and support vector machine methods were used to discriminate between tumor types. The combination of parameters offered an objective evaluation of the SWI pattern in gliomas and brain metastases. The model accurately predicted 88% of glioblastoma, according to the quantification of intratumoral SWI features, failing to discriminate the other types. SWI is not normally used to classify brain tumors, however fractal-based multi-parametric computational analysis can be used to characterize intratumoral SWI patterns to objectively quantify tumors-related features. Specific parameters still have to be identified to provide completely automatic computerized differential diagnosis. Copy rights belong to original authors. Visit the link for more info

Gliomas, Opioids, Coercive Citations, Green New Deal quadshotnews@gmail.com @QuadShotNews

Dra. Camilla Yamada, autora do MOC, comenta os dados de um estudo esperado em neuro-oncologia apresentado na ASCO 2019. O estudo avaliou o benefício do tratamento concomitante da radioterapia com temozolamida em pacientes com gliomas IDH mutado ou IDH selvagem, demonstrando que não houve benefício em associar temozolamida à raditerapia. Portanto, mantendo temozolamida de manutenção por 12 ciclos.

In this episode of Causes or Cures, Dr. Erin Stair interviews Dr. Fiorella Belpoggi about the potential health risks of wireless technology and radiation from EMFs (electromagnetic fields). The safety of EMFs is in the news due to the rollout of 5G and because of a recently resurfaced petition to the World Health Organization that was signed by 250 scientists warning about EMF exposure and health effects. Dr. Belpoggi is the head of research at the Ramazzini Institute in Italy and Director of the Cesare Mal-toni Cancer Research Center, where she has worked since 1981. She has published over 100 peer-reviewed papers and has done research on a variety of environmental exposures, including pesticides, plastics, food additives and hormones. To date, she has performed the largest animal study involving EMF ( cell phone) exposure and cancer risk, which is covered in this interview, along with her recommendations for use of cell phones and wireless technology. ( For those with short attention spans, a summary of her recommendations will also be included in Dr. Stair's blog at bloomingwellness.com.) Dr. Belpoggi is a fellow of the International Academy of Toxicologic Pathology; a member of the European Society of Toxicologic Pathology, and she has served as an expert witness or adviser for the European Parliament, the World Health Organization, the Directorate General for Health and Consumer Affairs, and the European Center for Environmental Health. Follow Erin on Instagram Here! To read Dr. Erin Stair's new comedic book on the Wellness Industry, click here: Yours in Wellness, Krystal Heeling.

Nesse episódio do Gene Highlights, o Dr. Antônio Rocha entrevista o Dr. Felipe Alba, que fala sobre a aplicação do SWI nos estudos dos gliomas. Confira a agenda de reuniões do Gene em https://spr.org.br/grupos-de-estudos/gene-grupo-de-estudos-de-neurorradiologia/ e participe online (https://spr.org.br/cursos-via-web/). Abaixo, segue o artigo de referência dessa entrevista: Susceptibility-Weighted Imaging of Glioma: Update on Current Imaging Status and Future Directions. https://www.ncbi.nlm.nih.gov/pubmed/27227542

Dr. José Marcus Rotta

The year 2016 marked the transition in an era of neuro-oncology from histologic-based diagnoses of primary brain tumors to a molecular and genetic classification system. Drs. Jorg Dietrich (neuro-oncology) and Brian Nahed (neurosurgery) of Massachusetts General Hospital discuss what the reclassification of primary glial neoplasms means for their patients. Produced by James E. Siegler. Music by Lee Rosevere, Ian Sutherland, and Lovira. Voiceover by Erika Mejia. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making. REFERENCES Schiff D. Low-grade Gliomas. Continuum (Minneap Minn). 2017;23:1564-1579. Wen PY and Huse JT. 2016 World Health Organization Classification of Central Nervous System Tumors. Continuum (Minneap Minn). 2017;23:1531-1547. McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, Olivi A, Brem H and Quinones-Hinojosa A. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63:700-7; author reply 707-8. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW and Berger MS. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26:1338-45. Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR and Mehta MP. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30:3065-70.

Senator McCain has a malignant brain tumor called a Glioblastoma Multiforme, orglioblastoma or GBM for short. He’s not the first person politically connected to get one of these things. I think this is what Senator Ted Kennedy had back in 2008 and also Beau Biden, Joe Biden’s son died of a glioblastoma. Glioblastomas are one of a class of brain tumors called Gliomas. Gliomas can be low grade which are considered pre-malginant or pre-cancerous or they can be high grade malignancies such as GBMs.   Today 2 Docs Talk about Glioblastoma Multiforme, and the difficulties associated with treating - or not treating - the tumor.  Resources: Don't Tell John McCain to Fight His Cancer FDA approval of Optune device for Glioblastoma 2 Docs Talk episode on hospice Be sure and subscribe in iTunes or Stitcher if you haven’t already.  And you know we’d appreciate it so much if you would tell your friends about 2 Docs Talk! Listen on iTunes Listen on Stitcher Now Available on Google Play Music!  

This week, we examine some TRP-y causes of birth defects, study the molecular makeup of a scare group of childhood cancers, and end on a high note with the devious ways cuckoos deceive other birds. To see the covers and find out more about us, head over to: https://www.coverslipspodcast.com Stay in touch at http://twitter.com/CoverslipsPod or shoot us an email at info@coverslipspodcast.com

Dr Nada Jabado speaks with ecancertv at AACR 2016 about epigenetic mutations found in high grade gliomas. Single nucleotide polymorphisms that occur within the epigenome can alter the structural assembly of proteins and the function of cellular components, with Dr Jabado reporting on a handful of mutations that can alter cell architecture, resulting in a pluripotent and resistant cancer. She also describes the incidence of ependymoma, apparently not characterised by mutational origin, but a structural malformation that results in high mortality.

Based on the ABN's Autumn Meeting, David Burn interviews Anthony Chalmers on his lecture Gliomas - from Biology to Bedside. The ABN Autumn Meeting took place on 20th October 2016 in London.

DUSTIN’ OFF THE DEGREE - Awe of nature THIS DAY IN HISTORY - June 23 * 1960 - The United States Food and Drug Administration declares Enovid to be the first officially approved combined oral contraceptive pill in the world * 1972 - Title 9 of the United States Civil Rights Act of 1964 is amended to prohibit sexual discrimination to any educational program receiving federal funds * 1964 - Joss Whedon, American director, producer, and screenwriter POLITICS AND RELIGION * Section 1 - The Pulse Shooting * Facebook removing Arab atheist groups and pages * North Carolina Dems are going to add protecting non-believers to their platform * Trump Questions whether or not Clinton is a Christian * Rumors of 5 year old girl raped by Syrian refugees found to be a hoax SCIENCE AND TECHNOLOGY * A new moon has been found orbiting earth * Gliomas found to be more common for people who went to college * Genes found that activate after death FEEDBACK * Brian via email * William via Facebook * @RandyLaMonda via Twitter * Gerardo via Email Email us at contact@atheistnomads.com or call us at (541) 203-0666. This episode is brought to you by: Dark Matter Sponsor - >US$35.00 * Travis Megee Nuclear Sponsor - US$20.00 - US$35.00 per month * Russ from the Kitsap Atheists & Agnostics * Frank * Darryl Goossen Platinum Sponsor - US$8.00 - US$19.00 per month * Virginia Dawn * Paul Burkey * BT Motley * George Gold Sponsor - US$4.00 - US$7.00 per month * The Flying Skeptic * Renee Davis-Pelt * Mark * Mike * LaTonya * Duncan * Jaded Zappa * Alex * Will * Henry * Alan * Rachel * Bumboclaat * Inciting Incident Bronze Sponsor - < US$4.00 per month * Peter * Heather * Shawn * Al from South Carolina * Archway Hosting provides full featured web hosting for a fraction of the cost of traditional shared hosting. You get all the benefits of shared hosting, without the sticker shock or extra fees. Check them out at archwayhosting.com. You can find us online at www.atheistnomads.com, follow us on Twitter @AtheistNomads, like us on Facebook, email us at contact@atheistnomads.com, and leave us a voice mail message at (541) 203-0666. Theme music is provided by Sturdy Fred.

DUSTIN' OFF THE DEGREE - Awe of nature THIS DAY IN HISTORY - June 23 * 1960 - The United States Food and Drug Administration declares Enovid to be the first officially approved combined oral contraceptive pill in the world * 1972 - Title 9 of the United States Civil Rights Act of 1964 is amended to prohibit sexual discrimination to any educational program receiving federal funds * 1964 - Joss Whedon, American director, producer, and screenwriter POLITICS AND RELIGION * Section 1 - The Pulse Shooting * Facebook removing Arab atheist groups and pages * North Carolina Dems are going to add protecting non-believers to their platform * Trump Questions whether or not Clinton is a Christian * Rumors of 5 year old girl raped by Syrian refugees found to be a hoax SCIENCE AND TECHNOLOGY * A new moon has been found orbiting earth * Gliomas found to be more common for people who went to college * Genes found that activate after death FEEDBACK * Brian via email * William via Facebook * @RandyLaMonda via Twitter * Gerardo via Email Email us at contact@atheistnomads.com or call us at (541) 203-0666. This episode is brought to you by: Dark Matter Sponsor - >US$35.00 * Travis Megee Nuclear Sponsor - US$20.00 - US$35.00 per month * Russ from the Kitsap Atheists & Agnostics * Frank * Darryl Goossen Platinum Sponsor - US$8.00 - US$19.00 per month * Virginia Dawn * Paul Burkey * BT Motley * George Gold Sponsor - US$4.00 - US$7.00 per month * The Flying Skeptic * Renee Davis-Pelt * Mark * Mike * LaTonya * Duncan * Jaded Zappa * Alex * Will * Henry * Alan * Rachel * Bumboclaat * Inciting Incident Bronze Sponsor - < US$4.00 per month * Peter * Heather * Shawn * Al from South Carolina * Archway Hosting provides full featured web hosting for a fraction of the cost of traditional shared hosting. You get all the benefits of shared hosting, without the sticker shock or extra fees. Check them out at archwayhosting.com. You can find us online at www.atheistnomads.com, follow us on Twitter @AtheistNomads, like us on Facebook, email us at contact@atheistnomads.com, and leave us a voice mail message at (541) 203-0666. Theme music is provided by Sturdy Fred.

On Friday, Nov. 6, a press conference was held featuring a preview of the meeting with the conference co-chairs: Levi A. Garraway, MD, PhD, Dana-Farber Cancer Institute, Boston (AACR); Lee J. Helman, MD, NCI, Bethesda, Maryland (NCI); and Jean-Charles Soria, MD, PhD, Institut Gustave Roussy, Villejuif, France (EORTC). The press conference also highlighted the following research: Loss of SMAD4 Gene in Certain Colorectal Cancers is Associated With Poor Prognosis; and Pediatric Low-grade Gliomas with CRAF Fusions May Require Differential and Combinatorial Targeted Therapies

Gliomas are a type of brain tumour, and are usually called 'low grade' or 'high grade'. What do these terms mean?

In the most recent episode of This Week in Pediatric Oncology, co-hosts Dr. Nilay Shah (Nationwide Children’s Hospital), Dr. Timothy Cripe (Nationwide Children’s Hospital), and Dr. Lionel Chow (Cincinnati Children’s) discuss the promising results of a study published in the July issue of Journal of Clinical Oncology among children with an aggressive brain tumor after receiving immunotherapy. To see a summary of the study, click here. 

April 05, 2012 Host Dr. Tim Cripe welcomes back co-host Dr. Lionel Chow to discuss somatic mutations in pediatric brain tumors. After recapping the consensus paper on molecular subgroups in medulloblastoma discussed in TWiPO episode 22 (Brain Tumor Round Robin) Dr Chow highlights the significance of the driver mutations in histone H3.3 in pediatric glioblastoma. Results of whole exome sequencing have shown that significantly more somatic mutations are present in adult tumors compared to pediatric tumors. This difference might suggest a reason for better success rates in pediatric tumors and possibly more escape mechanisms in adult tumors. Dr. Chow also discusses a paper published by the Pediatric Cancer Genome Project (a St. Jude Children's Research Hospital–Washington University collaboration) on somatic histone H3 alterations in diffuse intrinsic pontine glioma (DIPG). The findings are significant in showing that this mutation is present in 36% of non-brain stem gliomas and in 78% of brain stem gliomas, but in none of the other pediatric tumor types. Please send comments and questions to twipo@solvingkidscancer.org Papers discussed: Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012 Apr;123(4):465-72. Epub 2011 Dec 2.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306779/ Schwartzentruber J, Korshunov A, Liu XY, Jones DT, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012 Jan 29;482(7384):226-31. doi: 10.1038/nature10833. http://www.ncbi.nlm.nih.gov/pubmed/22286061 Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012 Jan 29;44(3):251-3. doi: 10.1038/ng.1102. St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project.http://www.ncbi.nlm.nih.gov/pubmed/22286216

Background and purpose: The aim of the present analysis was to assess the feasibility, toxicity, and the tumor control of reirradiation as a salvage treatment for progressive pediatric non-pontine high-grade gliomas (HGG). Patients and methods: The database of the Reference Center for Radiation Oncology of the German HIT (HIT = German acronym for brain tumor) treatment network for childhood brain tumors was screened for children who were reirradiated for progressive non-pontine HGG. Results: We identified eight patients (WHO grade III: n = 5; WHO grade IV: n = 3) who underwent reirradiation between April 2006 and July 2012. Median age was 13.5 years at primary diagnosis and 14.8 years at first progression. All patients initially underwent surgery (incomplete resection, n = 7; biopsy, n = 1) followed by radiochemotherapy. Relapses occurred inside (n = 2), at the margin (n = 4), and outside of the preirradiated area (n = 2). In all patients, reirradiation was tolerated well without significant acute toxicity. Temporary clinical improvement and tumor regression on magnetic resonance imaging (MRI) following reirradiation was reported (n = 3). However, all patients finally died by disease progression. Median survival time was 26.2 months from initial diagnosis and 11.4 months after first progression. Median time interval between initial radiotherapy and first reirradiation was 9.0 months. In six patients, all macroscopic tumor deposits were reirradiated. In these patients, median progression-free (overall) survival from the start of reirradiation was 2.4 (4.6) months. Conclusion: Our analysis, although based on a limited patient number, suggests that reirradiation of progressive non-pontine HGG is feasible in children. Benefit in terms of quality of life and/or survival needs to be assessed in a prospective and ideally in a randomized manner.

Editor's Audio Summary by Mary McGrae McDermott, MD, Senior Editor, the Journal of the American Medical Association, for the November 06, 2013 issue

Thu, 25 Oct 2012 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/14957/ https://edoc.ub.uni-muenchen.de/14957/1/Fu_Peng.pdf Fu, Peng ddc:610, ddc:600, Medizinische Fakultät

In this month's Cell Podcast, we cover how a scorpion venom-derived peptide might be used to treat glioma, with Harald Sontheimer (0:00) (Trends in Neurosciences June issue), visualizing the immune system in 3D to monitor inflammation in a whole organism, with Eric Skaar (7:58) (Cell Host and Microbe June 14 issue), and understanding how mothers tolerate the "alien within" during pregnancy, with Alexander Rudensky (14:31) (Cell July 6 issue). Plus, sample a selection of the hottest new papers from Cell Press (22:01).

Krüppel-like factor 8 (KLF8) has only recently been identified to be involved in tumor cell proliferation and invasion of several different tumor entities like renal cell carcinoma, hepatocellular carcinoma and breast cancer. In the present study, we show for the first time the expression of KLF8 in gliomas of different WHO grades and its functional impact on glioma cell proliferation. In order to get information about KLF8-mRNA regulation qPCR was performed and did not reveal any significant difference in samples (n = 10 each) of non-neoplastic brain (NNB), low-grade gliomas (LGG, WHO°II) and glioblastomas (GBM, WHO°IV). Immunohistochemistry of tissue samples (n = 7 LGG, 11 AA and 12 GBM) did not show any significant difference in the fraction of KLF8-immunopositive cells of all analyzed cells in LGG (87%), AA (80%) or GBM (89%). Tissue samples from cerebral breast cancer metastasis, meningiomas but also non-neoplastic brain demonstrated comparable relative cell counts as well. Moreover, there was no correlation between KLF8 expression and the expression pattern of the assumed proliferation marker Ki67, which showed high variability between different tumor grade (9% (LGG), 6% (AA) and 15% (GBM) of Ki67-immunopositive cells). Densitometric analysis of Western blotting revealed that the relative amount of KLF8-protein did also not differ between the highly aggressive and proliferative GBM (1.05) compared to LGG (0.93; p

Mon, 5 Jul 2010 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/11799/ https://edoc.ub.uni-muenchen.de/11799/1/Beck_Tobias_J.pdf Beck, Tobias ddc:610, ddc:600, Medizinische Fakultät

ResearchToPractice.com/SMCNS09 – Introduction and discussion of the pathology of gliomas. Moderated by Neil Love, MD. Produced by Research To Practice.

Guest: Mitchel Berger, MD Host: Bill Rutenberg, MD Malignant Glioma: A diagnosis your patient wants do not want to receive. As their primary physician what more can you tell your patient? What does the latest research indicate about the pathobiology of Gliomas? In this segment our guest Dr. Mitchel Berger, Professor and Chair of Neurological Surgery at the University of California, San Francisco, talks with host Dr. Bill Rutenberg about the latest Glioma research. They discuss the genetic advances that may lead to new treatments including a possible vaccination currently being developed that could one day replace mainstay treatments including radiation and chemotherapy.

Mon, 5 Aug 2002 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/580/ https://edoc.ub.uni-muenchen.de/580/1/Horst_Edward_van_der.pdf Htun van der Horst, Edward ddc:540, ddc:500, Fakultät für Chemie und Pharmazie

Nine human malignant gliomas (2 astrocytomas grade III and 7 glioblastomas) were analyzed using comparative genomic hybridization (CGH). In addition to the amplification of the EGFR gene at 7p12 in 4 of 9 cases, six new amplification sites were mapped to 1q32, 4q12, 7q21.1, 7q21.2-3, 12p, and 22q12. Nonrandom chromosomal gains and losses were identified with overrepresentation of chromosome 7 and underrepresentation of chromosome 10 as the most frequent events (1 of 2 astrocytomas, 7 of 7 glioblastomas). Gain of a part or the whole chromosome 19 and losses of chromosome bands 9pter-23 and 22q13 were detected each in five cases. Loss of chromosome band 17p13 and gain of chromosome 20 were revealed each in three cases. The validity of the CGH data was confirmed using interphase cytogenetics with YAC clones, chromosome painting in tumor metaphase spreads, and DNA fingerprinting. A comparison of CGH data with the results of chromosome banding analyses indicates that metaphase spreads accessible in primary tumor cell cultures may not represent the clones predominant in the tumor tissue.